Chanhyun Park, Ph.D., FAHA

Dr. Chanhyun Park

Assistant Professor of Health Outcomes

Dr. Chanhyun Park is a health outcomes researcher and assistant professor in the Health Outcomes Division and an affiliated faculty member of the Oden Institute for Computational Engineering & Sciences at The University of Texas at Austin (UT). Before joining UT, she served as a health scientist at the Centers for Disease Control and Prevention (CDC) and as an assistant professor at Northeastern University School of Pharmacy.

Her research evaluates the clinical, economic, and humanistic outcomes of healthcare services and medications using real-world data and advanced quantitative methods. Her work spans pharmacoepidemiology, pharmacoeconomics, meta-analysis, causal inference, and artificial intelligence (AI) and machine learning. Through these approaches, she aims to understand how patients use and respond to treatments, identify patients at high risk for treatment-related adverse events, reduce avoidable healthcare use and the financial burden on patients and families, and advance health equity. Her current research program focuses on improving health outcomes at the intersection of cardiovascular disease, metabolic conditions, and cancer.

Her research has been supported by federal agencies and foundations, including the National Institutes of Health (NIH), the American Heart Association (AHA), and the American Cancer Society (ACS). She has earned multiple awards, including best poster awards at national and international conferences. She is a Fellow of the American Heart Association (FAHA) and received the 2024 UT College of Pharmacy Outstanding Graduate Teaching and Mentoring Award.

Education 
Ph.D., The University of Texas at Austin
M.Ed., The University of Texas at Austin
M.Pharm, Sookmyung Women’s University
B.Pharm, Sookmyung Women’s University

Research Profile 
ORCid
NCBI
Google Scholar
Research Gate
LinkedIn

Selected Recent Publications
*Denotes student(s)/trainee(s) at the time of the study.

CORE Area: Patient-Centered Outcomes Research

Yoon H*, Kim Y*, Han S*, Suh HS, Park C. Long-term survival prediction in older women with stage I-II breast cancer using decision tree-based machine learning. Journal of Geriatric Oncology. 2026 Mar;17(2):102828. doi: 10.1016/j.jgo.2025.102828.

Han S*, Lee H*, Park C. Comorbidity cluster trajectories across the care continuum in older women with breast cancer initiating adjuvant endocrine therapy. Journal of Geriatric Oncology. 2026 Mar;17(2):102852. doi: 10.1016/j.jgo.2026.102852.

Kim Y*, Lee J, Suh HS, Park C. Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies. Journal of Geriatric Oncology. 2026 Jan;17(1):102779. doi: 10.1016/j.jgo.2025.102779.

Liu YS*, Barner JC, Lawson KL, Liu Y, Park C. Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment. Therapeutic Advances in Medical Oncology.  2025 Sep 23;17:17588359251378245. doi: 10.1177/17588359251378245.

Le N*, Avanceña ALV, Liu Y, Shen C, Park C. Mediating effects of social and clinical factors on racial disparities in cardiovascular outcomes following anthracycline therapy in older women with breast cancer. Journal of Geriatric Oncology. 2025 Aug 5;16(7):102333. doi: 10.1016/j.jgo.2025.102333.

CORE Area: Healthcare Systems Research

Kenawy AS*, Baffoe JO*, Park C. Change in adherence to oral antidiabetic medications before and after prostate cancer diagnosis: A group-based trajectory modeling approach. Clinical Drug Investigation. 2026 Aug;46(8):897-909. doi: 10.1007/s40261-026-01569-5.

Lin KP, Arellano BA*, Park C, Block G, Stewart M. Effect of best practice advisory on glucagon prescribing in patients with diabetes at a federally qualified health center. Diabetes, Obesity, and Cardiometabolic CARE. 2026;1(2):298-303. doi: 10.2337/doc25-0032.

Ng BP, LaManna JB, Hsieh M, Hawkins GT, Park C. Digital divide and diabetes self-management education and support among Medicare beneficiaries. Science of Diabetes Self-Management and Care. 2026 Feb;52(1):25-34. doi: 10.1177/26350106251401498.

Guerra S*, Litten K, Kenawy A*, Park C, Stewart M. Assessing prescribing patterns of nonstatins as add-on therapy for secondary prevention in a federally qualified health center. Pharmacy. 2025 Sep 6;13(5):129. doi: 10.3390/pharmacy13050129.

Ng BP, Hawkins GT, Massey M, LaManna JB, Park C. Digital divide among beneficiaries and Medicare diabetes prevention program. American Journal of Preventive Medicine. 2024 Nov;67(5):746-752. doi: 10.1016/j.amepre.2024.06.019.

CORE Area: Health Economics and Outcomes Research

Wu LW*, Heo JH, Fa A*, Ng BP, Park C. Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period. Journal of Managed Care & Specialty Pharmacy. 2026;32(4):445-457. doi: 10.18553/jmcp.2026.32.4.445.

Park C, Liu YS*, Kenawy AS*, Lin YH*, Liu Y, Heo JH. Cardiovascular adverse events and associated costs of CDK4/6 inhibitors in patients with breast cancer. Journal of the National Comprehensive Cancer Network. 2025 Apr 18;23(5):e257001. doi: 10.6004/jnccn.2025.7001.

Le N*, Han S*, Kenawy AS*, Kim Y*, Park C. Machine learning-based prediction of unplanned readmission due to major adverse cardiac events among hospitalized patients with blood cancers. Cancer Control. 2025 Jan-Dec;32:10732748251332803. doi: 10.1177/10732748251332803.

Byun JY*, Aiyeolemi AA*, Qdaisat A, Park C. Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer. Cancer. 2024;130(20):3412-3425. doi: 10.1002/cncr.35424.

Han S*, Sohn TJ*, Ng BP, Park C. Predicting unplanned readmission due to cardiovascular disease in hospitalized patients with cancer: a machine learning approach. Scientific Reports. 2023 Aug 18;13(1):13491. doi: 10.1038/s41598-023-40552-4.

Graduate Courses

  • PGS 384S Introduction to Epidemiology (Topic: Measures, Study Design, Bias, Machine Learning)
  • PGS 393T Pharmacoeconomics (Topic: Decision Analysis, Markov Modeling, Real-World Data) 
  • PGS 390J Data Analysis in Healthcare (Topic: Tables and Figures)
  • PGS 196S Seminar in Pharmacy (Topic: Databases in Health Outcomes Research)

Pharm.D. Courses

  • PHM 394F Principles in Pharmacoeconomics and Pharmacy Management (Topic: Introduction to Pharmacoeconomics, Costs, Cost-Benefit Analysis)

Significant/Recent Activities

National and International Service Activities

  • Member, Cancer and Aging Research Group (CARG) - Health Services Core, Junior CARG Board
  • Member, Journal of Managed Care & Specialty Pharmacy (JMCP) - Editorial Advisory Board
  • Mentor, Academy of Managed Care Pharmacy (AMCP) - Peer Review Academy
  • Grant Reviewer, American Heart Association (AHA)
  • Mentor, Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (AIM-AHEAD) - All of Us Program

University/College Service Activities

  • Chair, Health Outcomes Division AI Policy Task Force
  • Advisor, AMCP Student Chapter
  • Advisor, ISPE Student Chapter
  • Advisor, Baylor Scott & White (BSW) Fellowship
  • Member, PharmD Financial Aid Committee and Graduate Financial Aid Committee
  • Mentor, UTeams
C-More Lab. Cardio-Metabolic Oncology Research and Evaluation for Health Outcomes


Dr. Park and her mentees collaborate with external clinical and methodological collaborators through the C-MORE (Cardio-Metabolic Oncology Research and Evaluation for Health Outcomes) research group, which aims to “see more” where cardio-metabolic disease and oncology meet through real-world evidence to advance health outcomes.  

Recent Research Awards in C-MORE Research Group

  • KSEA-KUSCO Graduate Scholarship (Mentee: Yeijin Kim) - 2026 Korean-American Scientists and Engineers Association (KSEA)
  • Spotlight Poster (Mentee: Nguyen Le) - 2025 International Society for Pharmacoepidemiology (ISPE) Annual Meeting 
  • Best Student Poster Research Presentation (Mentee: Ted Sohn) - 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting
  • Top 5% Finalist Poster (Mentee: Ted Sohn) - 2025 ISPOR Annual Meeting
  • Student Travel Grant Award (Mentees: Ted Sohn, Yeijin Kim) - 2025 ISPOR Annual Meeting
  • Best Graduate Student Poster (Mentee: Li-Wei Wu) - 2025 Academy of Managed Care Pharmacy (AMCP) Annual Meeting
  • Student Travel Grant Award (Mentee: Yi-Shao Liu) - 2024 ISPOR Annual Meeting
  • Top 5% Finalist Poster (Mentee: Sola Han) - 2023 ISPOR Annual Meeting

Recent Publications in C-MORE Research Group
*Denotes mentee(s) at the time of the study.

Cardio-Oncology (Breast Cancer Focus)

Yoon H*, Kim Y*, Han S*, Suh HS, Park C. Long-term survival prediction in older women with stage I-II breast cancer using decision tree-based machine learning. Journal of Geriatric Oncology. 2026 Mar;17(2):102828. doi: 10.1016/j.jgo.2025.102828.

Han S*, Lee H*, Park C. Comorbidity cluster trajectories across the care continuum in older women with breast cancer initiating adjuvant endocrine therapy. Journal of Geriatric Oncology. 2026 Mar;17(2):102852. doi: 10.1016/j.jgo.2026.102852.

Park C, Kim K, Abifaraj NB*, Bryant SD*, Heo JH. Integration of pre-existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer. Therapeutic Advances in Drug Safety. 2026;17:20420986251414588. doi: 10.1177/20420986251414588.

Park C, Liu YS*, Kenawy AS*, Lin YH*, Liu Y, Heo JH. Cardiovascular adverse events and associated costs of CDK4/6 inhibitors in patients with breast cancer. Journal of the National Comprehensive Cancer Network. 2025 Apr 18;23(5):e257001. doi: 10.6004/jnccn.2025.7001.

Liu YS*, Barner JC, Lawson KL, Liu Y, Park C. Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment. Therapeutic Advances in Medical Oncology. 2025 Sep 23;17:17588359251378245. doi: 10.1177/17588359251378245.

Le N*, Avanceña ALV, Liu Y, Shen C, Park C. Mediating effects of social and clinical factors on racial disparities in cardiovascular outcomes following anthracycline therapy in older women with breast cancer. Journal of Geriatric Oncology. 2025 Aug 5;16(7):102333. doi: 10.1016/j.jgo.2025.102333.

Liu YS*, Liu Y, Park C. Association of cardiovascular disease with health-related quality of life among older women with early-stage breast cancer undergoing adjuvant endocrine therapy. Journal of Geriatric Oncology. 2023 Sep;14(7):101598. doi: 10.1016/j.jgo.2023.101598.

Liu YS*, Dong K*, Park C. Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis. Reviews in Cardiovascular Medicine. 2023 Nov 9;24(11):309. doi: 10.31083/j.rcm2411309.

Park C, Park SK*, Upshaw JN, Schonberg MA. In-hospital mortality, length of stay, and hospital costs for hospitalized breast cancer patients with comorbid-heart failure in the USA. Current Medical Research and Opinion. 2022;37(12):2043-2047. doi: 10.1080/03007995.2021.1980775.

Cardio-Oncology (Lung Cancer Focus)

Kim Y*, Lee J, Suh HS, Park C. Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies. Journal of Geriatric Oncology. 2026 Jan;17(1):102779. doi: 10.1016/j.jgo.2025.102779.

Kim Y*, Liu Y, Suh HS, Park C. Factors associated with cause-specific mortality in older patients with advanced NSCLC treated with PD-1 inhibitors: A US Population-based cohort study. Cancer Control. 2025 Jan-Dec:32:10732748251380932. doi: 10.1177/10732748251380932.

Byun JY*, Aiyeolemi AA*, Qdaisat A, Park C. Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer. Cancer. 2024 Jun 7. doi: 10.1002/cncr.35424.

Byun JY*, Han S*, Liu Y, Park C. Sex-specific risk of heart failure and acute myocardial infarction associated with osimertinib in older patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology. doi: 10.1177/1758835924126472

Byun JY*, Han S*, Qdaisat A, Park C. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer. Expert Opinion on Drug Safety. 2024 Aug;23(8):1007-1015. doi: 10.1080/14740338.2023.2294924.

Cardio-Oncology (Other Cancer Focus)

Kenawy AS*, Baffoe JO*, Park C. Change in adherence to oral antidiabetic medications before and after prostate cancer diagnosis: A group-based trajectory modeling approach. Clinical Drug Investigation. 2026 Aug;46(8):897-909. doi: 10.1007/s40261-026-01569-5.

Le N*, Han S*, Kenawy AS*, Kim Y*, Park C. Machine learning-based prediction of unplanned readmission due to major adverse cardiac events among hospitalized patients with blood cancers. Cancer Control. 2025 Jan-Dec:32:10732748251332803. doi: 10.1177/10732748251332803.

Park SK*, Park L*, Silverman C*, Heo JH, Park C. Association of congestive heart failure with hospital outcomes among renal cancer patients in the United States: Analysis of Nationwide Inpatient Sample. Expert Review of Pharmacoeconomics & Outcomes Research. 2021;21(3):395-402. doi: 10.1080/14737167.2021.1897576.

Yu A*, Thaliffdeen R*, Park SK*, Park C. Hospital outcomes and costs for prostate cancer patients with comorbid heart failure by age group: An analysis of the US Nationwide Inpatient Sample. Journal of Evaluation in Clinical Practice. 2023 Sep;29(6):1016-1024. doi: 10.1111/jep.13869.

Cardio-Oncology (Overall Cancer)

Wu LW*, Heo JH, Fa A*, Ng BP, Park C. Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period. Journal of Managed Care & Specialty Pharmacy. 2026;32(4):445-457. doi: 10.18553/jmcp.2026.32.4.445.

Han S*, Sohn TJ*, Ng BP, Park C. Predicting unplanned readmission due to cardiovascular disease in hospitalized patients with cancer: a machine learning approach. Scientific Reports. 2023 Aug 18;13(1):13491. doi: 10.1038/s41598-023-40552-4. 

Han S*, Sohn TJ*, Avanceña ALV, Park C. Rate, timing, and duration of unplanned readmissions due to cardiovascular diseases among hospitalized patients with cancer in the United States. Reviews in Cardiovascular Medicine. 2023 Nov 23;24(11):326. doi: 10.31083/j.rcm2411326.

Park C, Han S*, Mehta S*, Litten KP, Ng BP. Prevalence of primary and secondary hypertension among hospitalized patients with cancer in the United States. Chronic Illness. 2025 Mar;21(1):42-55. doi: 10.1177/17423953231196613.

Contact Information
Phone:
Campus location:
PHR 3.210D

US Mail Address:
UT College of Pharmacy-Health Outcomes
2409 University Avenue, STOP A1930
Austin, TX 78712-1120

FEDEX Address:
2409 University Avenue 
PHR 3.210D
The University of Texas at Austin
Austin, TX 78712